Whitehawk Therapeutics, Inc.(WHWK)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Whitehawk Therapeutics, Inc. (WHWK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WHWK at 26.4/100 on a 32-signal composite quality model, placing it at rank #2,729 of 3,064 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.3) and earnings quality (16.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Whitehawk Therapeutics, Inc. reports net income of $-16.6M, free cash flow of $-14.5M. Top institutional holders of WHWK by reported 13-F value include Yu Fan, ACUTA CAPITAL PARTNERS, QVT Financial, based on the most recent SEC filings. WHWK trades on the Nasdaq exchange and files with the SEC under CIK 1422142. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WHWK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Whitehawk Therapeutics, Inc. directly from SEC EDGAR.